Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: UBE2E3

Gene summary for UBE2E3

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

UBE2E3

Gene ID

10477

Gene nameubiquitin conjugating enzyme E2 E3
Gene AliasUBCH9
Cytomap2q31.3
Gene Typeprotein-coding
GO ID

GO:0000209

UniProtAcc

Q969T4


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
10477UBE2E3HTA11_3410_2000001011HumanColorectumAD3.31e-10-5.05e-010.0155
10477UBE2E3HTA11_3361_2000001011HumanColorectumAD3.71e-03-5.12e-01-0.1207
10477UBE2E3HTA11_696_2000001011HumanColorectumAD2.49e-19-5.25e-01-0.1464
10477UBE2E3HTA11_866_2000001011HumanColorectumAD1.83e-13-4.63e-01-0.1001
10477UBE2E3HTA11_546_2000001011HumanColorectumAD8.56e-03-5.20e-01-0.0842
10477UBE2E3HTA11_9341_2000001011HumanColorectumSER4.26e-02-7.03e-01-0.00410000000000005
10477UBE2E3HTA11_10711_2000001011HumanColorectumAD5.65e-05-5.20e-010.0338
10477UBE2E3HTA11_7696_3000711011HumanColorectumAD1.62e-10-4.11e-010.0674
10477UBE2E3HTA11_99999970781_79442HumanColorectumMSS6.95e-03-2.51e-010.294
10477UBE2E3HTA11_99999971662_82457HumanColorectumMSS5.71e-03-3.04e-010.3859
10477UBE2E3HTA11_99999974143_84620HumanColorectumMSS3.32e-11-4.55e-010.3005
10477UBE2E3F007HumanColorectumFAP3.17e-02-3.89e-010.1176
10477UBE2E3A001-C-207HumanColorectumFAP4.17e-02-2.18e-010.1278
10477UBE2E3A015-C-203HumanColorectumFAP2.40e-25-4.43e-01-0.1294
10477UBE2E3A015-C-204HumanColorectumFAP8.52e-07-3.35e-01-0.0228
10477UBE2E3A014-C-040HumanColorectumFAP1.61e-04-5.09e-01-0.1184
10477UBE2E3A002-C-201HumanColorectumFAP5.45e-14-4.49e-010.0324
10477UBE2E3A002-C-203HumanColorectumFAP7.68e-09-3.24e-010.2786
10477UBE2E3A001-C-119HumanColorectumFAP6.96e-05-2.93e-01-0.1557
10477UBE2E3A001-C-108HumanColorectumFAP3.18e-17-3.80e-01-0.0272
Page: 1 2 3 4 5 6 7 8 9 10 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0000209ColorectumADprotein polyubiquitination78/3918236/187238.71e-062.06e-0478
GO:0070936ColorectumADprotein K48-linked ubiquitination27/391865/187231.31e-041.88e-0327
GO:0070534ColorectumADprotein K63-linked ubiquitination20/391856/187237.57e-034.58e-0220
GO:00002091ColorectumSERprotein polyubiquitination58/2897236/187231.69e-043.18e-0358
GO:00002092ColorectumMSSprotein polyubiquitination72/3467236/187235.19e-061.42e-0472
GO:00709361ColorectumMSSprotein K48-linked ubiquitination27/346765/187231.40e-053.18e-0427
GO:00705341ColorectumMSSprotein K63-linked ubiquitination21/346756/187236.51e-047.06e-0321
GO:00709362ColorectumFAPprotein K48-linked ubiquitination24/262265/187233.42e-061.23e-0424
GO:00002093ColorectumFAPprotein polyubiquitination59/2622236/187234.53e-061.52e-0459
GO:00709363ColorectumCRCprotein K48-linked ubiquitination19/207865/187235.34e-051.22e-0319
GO:00002094ColorectumCRCprotein polyubiquitination46/2078236/187239.91e-051.98e-0346
GO:00709367EndometriumAEHprotein K48-linked ubiquitination21/210065/187234.56e-061.18e-0421
GO:00002098EndometriumAEHprotein polyubiquitination44/2100236/187234.83e-044.97e-0344
GO:007093614EndometriumEECprotein K48-linked ubiquitination22/216865/187231.92e-065.79e-0522
GO:000020913EndometriumEECprotein polyubiquitination46/2168236/187232.65e-043.04e-0346
GO:007093610EsophagusHGINprotein K48-linked ubiquitination24/258765/187232.69e-069.49e-0524
GO:000020916EsophagusHGINprotein polyubiquitination58/2587236/187236.29e-061.97e-0458
GO:00705345EsophagusHGINprotein K63-linked ubiquitination17/258756/187231.07e-031.32e-0217
GO:00709794EsophagusHGINprotein K11-linked ubiquitination11/258729/187231.08e-031.32e-0211
GO:000020917EsophagusESCCprotein polyubiquitination170/8552236/187231.40e-161.09e-14170
Page: 1 2 3 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04120ColorectumADUbiquitin mediated proteolysis58/2092142/84651.46e-051.53e-049.76e-0558
hsa041201ColorectumADUbiquitin mediated proteolysis58/2092142/84651.46e-051.53e-049.76e-0558
hsa041202ColorectumSERUbiquitin mediated proteolysis39/1580142/84656.18e-033.66e-022.66e-0239
hsa041203ColorectumSERUbiquitin mediated proteolysis39/1580142/84656.18e-033.66e-022.66e-0239
hsa041204ColorectumMSSUbiquitin mediated proteolysis55/1875142/84655.02e-066.00e-053.68e-0555
hsa041205ColorectumMSSUbiquitin mediated proteolysis55/1875142/84655.02e-066.00e-053.68e-0555
hsa041206ColorectumFAPUbiquitin mediated proteolysis51/1404142/84651.55e-085.84e-073.55e-0751
hsa041207ColorectumFAPUbiquitin mediated proteolysis51/1404142/84651.55e-085.84e-073.55e-0751
hsa041208ColorectumCRCUbiquitin mediated proteolysis42/1091142/84659.98e-086.67e-064.52e-0642
hsa041209ColorectumCRCUbiquitin mediated proteolysis42/1091142/84659.98e-086.67e-064.52e-0642
hsa0412016EndometriumAEHUbiquitin mediated proteolysis41/1197142/84653.42e-064.27e-053.13e-0541
hsa0412017EndometriumAEHUbiquitin mediated proteolysis41/1197142/84653.42e-064.27e-053.13e-0541
hsa0412023EndometriumEECUbiquitin mediated proteolysis41/1237142/84657.86e-069.58e-057.14e-0541
hsa0412033EndometriumEECUbiquitin mediated proteolysis41/1237142/84657.86e-069.58e-057.14e-0541
hsa0412026EsophagusHGINUbiquitin mediated proteolysis49/1383142/84657.78e-081.33e-061.06e-0649
hsa04120111EsophagusHGINUbiquitin mediated proteolysis49/1383142/84657.78e-081.33e-061.06e-0649
hsa0412027EsophagusESCCUbiquitin mediated proteolysis122/4205142/84656.53e-207.29e-183.74e-18122
hsa0412036EsophagusESCCUbiquitin mediated proteolysis122/4205142/84656.53e-207.29e-183.74e-18122
hsa0412021LiverCirrhoticUbiquitin mediated proteolysis72/2530142/84651.32e-071.97e-061.21e-0672
hsa0412031LiverCirrhoticUbiquitin mediated proteolysis72/2530142/84651.32e-071.97e-061.21e-0672
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
UBE2E3SNVMissense_Mutationc.524C>Tp.Pro175Leup.P175LQ969T4protein_codingdeleterious(0)probably_damaging(0.996)TCGA-B6-A0RO-01Breastbreast invasive carcinomaFemale>=65III/IVUnknownUnknownSD
UBE2E3deletionFrame_Shift_Delc.503delNp.Leu169PhefsTer2p.L169Ffs*2Q969T4protein_codingTCGA-EW-A2FV-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapydocetaxelSD
UBE2E3SNVMissense_Mutationnovelc.41N>Ap.Ser14Asnp.S14NQ969T4protein_codingtolerated_low_confidence(0.2)benign(0.001)TCGA-EA-A3HS-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
UBE2E3deletionIn_Frame_Delnovelc.121_123delTCTp.Ser41delp.S41delQ969T4protein_codingTCGA-VS-A8EG-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
UBE2E3SNVMissense_Mutationc.443N>Ap.Ile148Asnp.I148NQ969T4protein_codingdeleterious(0)probably_damaging(0.974)TCGA-AA-3715-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownPD
UBE2E3insertionFrame_Shift_Insnovelc.382_383insGGTTTAATAACAAAATTAAATGp.Thr128ArgfsTer30p.T128Rfs*30Q969T4protein_codingTCGA-AM-5820-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
UBE2E3SNVMissense_Mutationnovelc.616N>Ap.Ala206Thrp.A206TQ969T4protein_codingdeleterious(0)probably_damaging(0.999)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
UBE2E3SNVMissense_Mutationnovelc.149N>Cp.Lys50Thrp.K50TQ969T4protein_codingtolerated(0.08)probably_damaging(0.932)TCGA-AJ-A5DW-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
UBE2E3SNVMissense_Mutationc.262N>Tp.Asp88Tyrp.D88YQ969T4protein_codingdeleterious(0)probably_damaging(0.988)TCGA-AX-A05Z-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapyadriamycinSD
UBE2E3SNVMissense_Mutationnovelc.164C>Tp.Thr55Ilep.T55IQ969T4protein_codingtolerated(0.14)probably_damaging(0.969)TCGA-AX-A2HC-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapypaclitaxelPD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1